Article Impact Level: HIGH Data Quality: STRONG Summary of Blood https://doi.org/10.1182/blood-2025-889 Dr. Mark Sorial et al.
Points
- Researchers utilized a Synthetic Survival Control framework to validate that relapse within twelve months is a significant predictor of poor survival in nodal mature T-cell lymphoma.
- The analysis of international cohorts revealed that patients with this early relapse marker had a hazard ratio for death of more than two compared to those without.
- This poor prognostic outlook remained consistent across various histological subgroups and persisted regardless of the initial stem cell transplantation status or baseline prognostic index scores.
- Patients exhibiting this early relapse marker showed significantly improved overall survival when treated with second-line novel agents compared to those receiving traditional chemotherapy regimens.
- These findings suggest that identifying early relapse risk could allow clinicians to prioritize targeted therapies or clinical trials over standard care for high-risk patient populations.
Summary
This retrospective global cohort study evaluated the prognostic significance of time-to-relapse within 12 months (TTR12) in patients with refractory nodal mature T-cell lymphomas (nMTCL). Researchers employed a causal inference framework, Synthetic Survival Controls, to analyze data from the PETAL (n=1414) and GELL (n=487) cohorts, alongside independent validation cohorts. The study aimed to overcome biases in observational data to estimate survival trajectories and compare the efficacy of second-line (2L) novel agents (NA) versus chemotherapy (CC) in high-risk groups.
The analysis demonstrated that TTR12 conferred significantly worse overall survival (OS) compared to patients without early relapse, with an adjusted hazard ratio (aHR) of 2.14 (95% CI: 1.58–2.90; p<0.001). This poor prognosis was consistent across subgroups, including PTCL-NOS (aHR 2.32, 95% CI: 1.51–3.55) and ALCL (aHR 3.34, 95% CI: 1.18–9.50). Independent validation cohorts confirmed these findings, with the observational cohort showing an HR of 3.72 (95% CI 1.85–7.46) and the phase 3 trial cohort showing an aHR of 3.71 (95% CI 2.17–6.32). Additionally, patients with a Prognostic Index for T-cell lymphoma (PIT) score of 4 had significantly higher odds of developing TTR12 (OR 3.64, 95% CI 1.07–12.38).
Regarding treatment efficacy, the study highlighted differential responses to 2L therapies based on TTR status. In patients with TTR12, 2L novel agents significantly improved OS compared to chemotherapy (aHR 0.60, 95% CI: 0.37–0.97; p=0.038). Conversely, in patients without TTR12, no significant survival difference was observed between NA and CC (aHR 0.82, 95% CI 0.51–1.32; p=0.407). These findings suggest TTR12 identifies a distinct high-risk group that may benefit from early prioritization of targeted therapies over canonical chemotherapy regimens.
Link to the article: https://ashpublications.org/blood/article/146/Supplement%201/889/551525/Early-time-to-relapse-as-a-predictor-of-survival
References
Sorial, M., Aniagboso, K., Buttermore, E., Lei, M., Kendall, E., Nasto, K., Koh, M. J., Han, J. X., Boussi, L., Malpica, L., Beltran, B., Korin, L., Stemmelin, G., Chiattone, C., Castro, D., Valvert, F., Vasquez, J., Quintero, H., Roa, M., … Jain, S. (2025). Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium. Blood, 146(Supplement 1), 889–889. https://doi.org/10.1182/blood-2025-889
